Silodosin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (3)Enzymes (2)Transporters (2)

Targets (3)Enzymes (2)Transporters (2)Biointeractions (7)

Identification

Name

Silodosin

Accession Number

DB06207

Type

Small Molecule

Groups

Approved

Description

Silodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

KAD 3213

KMD 3213

Rapaflo

Urief

External IDs

KAD-3213 / KMD-3213

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Rapaflo	Capsule	4 mg/1	Oral	Actavis Pharma Company	2009-03-23	Not applicable	US
Rapaflo	Capsule	8 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-23	Not applicable	US
Rapaflo	Capsule	8 mg/1	Oral	Actavis Pharma Company	2009-03-23	Not applicable	US
Rapaflo	Capsule	4 mg	Oral	Allergan Pharma Co.	2011-10-26	Not applicable	Canada
Rapaflo	Capsule	4 mg/1	Oral	Avera Mc Kennan Hospital	2015-05-01	Not applicable	US
Rapaflo	Capsule	8 mg/1	Oral	Physicians Total Care, Inc.	2010-09-15	Not applicable	US
Rapaflo	Capsule	8 mg	Oral	Allergan Pharma Co.	2011-10-26	Not applicable	Canada
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Silodyx	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	4 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU
Urorec	Capsule	8 mg	Oral	Recordati Ireland Ltd	2010-01-29	Not applicable	EU

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Rapilif	Ipca Urosciences
Silodyx	Recordati Industria Chimica e Farmaceutica S.p.A.
Urief	Watson Pharmaceuticals Inc.

Brand mixtures

Not Available

Categories

UNII

CUZ39LUY82

CAS number

160970-54-7

Weight

Average: 495.5345
Monoisotopic: 495.234491142

Chemical Formula

C₂₅H₃₂F₃N₃O₄

InChI Key

PNCPYILNMDWPEY-QGZVFWFLSA-N

InChI

InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

IUPAC Name

1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide

SMILES

C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F

Pharmacology

Indication

Treatment for symptomatic relief of benign prostatic hyperplasia

Structured Indications

Benign Prostatic Hyperplasia (BPH)

Pharmacodynamics

Silodosin is 583 times more selective for human alpha-1A receptors than alpha-1B receptors. It is also 56 times more selective for human alpha-1A receptors than alpha-1D. Silodosin does not prolong the QT interval.

Mechanism of action

Benign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Alpha-1A adrenergic receptor	Protein	yes	antagonist	Human	P35348	details
Alpha-1B adrenergic receptor	Protein	unknown	antagonist	Human	P35368	details
Alpha-1D adrenergic receptor	Protein	unknown	antagonist	Human	P25100	details

Absorption

Quickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours;
AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin.

Volume of distribution

49.5 L

Protein binding

97% bound to protein

Metabolism

Extensively metabolized in the liver. The main metabolite is generated via glucuronidation (KMD-3213G) by UDP-2B7. Oxidation by alcohol and aldehyde dehydrogenases produces the second major metabolite, KMD-3293. KMD-3213G accumulates in the plasma as it is very hydrophilic. KMD-3213G is also an active metabolite in which it has 50% of silodosin's inhibitory activity. KMD-3293 is inactive. Cytochrome P450 CYP 3A4 also generates some metabolites.

Route of elimination

Fecal (54.9%);
Renal (33.5%)

Half life

Silodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours;

Clearance

Plasma clearance = 10 L/h

Toxicity

Most common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acebutolol	Acebutolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Acetaminophen	The serum concentration of Silodosin can be increased when it is combined with Acetaminophen.	Approved
Adrafinil	Silodosin may decrease the vasoconstricting activities of Adrafinil.	Withdrawn
Afatinib	The serum concentration of Silodosin can be increased when it is combined with Afatinib.	Approved
Albendazole	The serum concentration of Silodosin can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Silodosin can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Silodosin can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Silodosin can be increased when it is combined with Alfentanil.	Approved, Illicit
Alfuzosin	Alfuzosin may increase the antihypertensive activities of Silodosin.	Approved, Investigational
Alprenolol	Alprenolol may increase the orthostatic hypotensive activities of Silodosin.	Approved, Withdrawn
Amantadine	The serum concentration of Silodosin can be increased when it is combined with Amantadine.	Approved
Amibegron	Silodosin may decrease the vasoconstricting activities of SR 58611.	Investigational
Aminohippuric acid	The serum concentration of Silodosin can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The serum concentration of Silodosin can be increased when it is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Silodosin can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Silodosin can be increased when it is combined with Amlodipine.	Approved
Amprenavir	The serum concentration of Silodosin can be increased when it is combined with Amprenavir.	Approved
Amrinone	Silodosin may increase the hypotensive activities of Amrinone.	Approved
Amsacrine	The serum concentration of Silodosin can be increased when it is combined with Amsacrine.	Approved
Anisodamine	Silodosin may decrease the vasoconstricting activities of Anisodamine.	Investigational
Apraclonidine	Silodosin may decrease the vasoconstricting activities of Apraclonidine.	Approved
Aprepitant	The serum concentration of Silodosin can be increased when it is combined with Aprepitant.	Approved, Investigational
Arbutamine	Silodosin may decrease the vasoconstricting activities of Arbutamine.	Approved
Arformoterol	Silodosin may decrease the vasoconstricting activities of Arformoterol.	Approved, Investigational
Arotinolol	Arotinolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Astemizole	The serum concentration of Silodosin can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The serum concentration of Silodosin can be increased when it is combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Silodosin can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Silodosin can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Silodosin can be increased when it is combined with Atorvastatin.	Approved
Azelastine	The serum concentration of Silodosin can be increased when it is combined with Azelastine.	Approved
Azelnidipine	Silodosin may increase the hypotensive activities of Azelnidipine.	Approved
Azimilide	Silodosin may increase the hypotensive activities of Azimilide.	Investigational
Azithromycin	The serum concentration of Silodosin can be increased when it is combined with Azithromycin.	Approved
Barnidipine	Silodosin may increase the hypotensive activities of Barnidipine.	Approved
Befunolol	Befunolol may increase the orthostatic hypotensive activities of Silodosin.	Experimental
Benidipine	Silodosin may increase the hypotensive activities of Benidipine.	Approved
Benzocaine	The serum concentration of Silodosin can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Silodosin can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betaxolol	Betaxolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Bevantolol	Bevantolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Bexarotene	The serum concentration of Silodosin can be decreased when it is combined with Bexarotene.	Approved, Investigational
Biperiden	The serum concentration of Silodosin can be increased when it is combined with Biperiden.	Approved
Bisoprolol	Bisoprolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Bitolterol	Silodosin may decrease the vasoconstricting activities of Bitolterol.	Withdrawn
Boceprevir	The serum concentration of Silodosin can be increased when it is combined with Boceprevir.	Approved, Investigational
Bopindolol	Bopindolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Bortezomib	The metabolism of Silodosin can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Silodosin can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Silodosin can be increased when it is combined with Bosutinib.	Approved
Brimonidine	Silodosin may decrease the vasoconstricting activities of Brimonidine.	Approved
Bromocriptine	The serum concentration of Silodosin can be increased when it is combined with Bromocriptine.	Approved, Investigational
Bucindolol	Silodosin may increase the antihypertensive activities of Bucindolol.	Investigational
Bufuralol	Bufuralol may increase the orthostatic hypotensive activities of Silodosin.	Experimental, Investigational
Bupranolol	Bupranolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Buprenorphine	The serum concentration of Silodosin can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Silodosin can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Silodosin can be increased when it is combined with Cabazitaxel.	Approved
Caffeine	The serum concentration of Silodosin can be increased when it is combined with Caffeine.	Approved
Canagliflozin	The serum concentration of Silodosin can be increased when it is combined with Canagliflozin.	Approved
Candesartan	The serum concentration of Silodosin can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Silodosin can be increased when it is combined with Captopril.	Approved
Carbamazepine	The serum concentration of Silodosin can be increased when it is combined with Carbamazepine.	Approved, Investigational
Carboxyamidotriazole	Silodosin may increase the hypotensive activities of Cai.	Investigational
Carteolol	Carteolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Carvedilol	The serum concentration of Silodosin can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Silodosin can be increased when it is combined with Caspofungin.	Approved
Celiprolol	Celiprolol may increase the orthostatic hypotensive activities of Silodosin.	Approved, Investigational
Ceritinib	The serum concentration of Silodosin can be increased when it is combined with Ceritinib.	Approved
Chloroquine	The serum concentration of Silodosin can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Silodosin can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Silodosin can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholesterol	The serum concentration of Silodosin can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Silodosin can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Silodosin can be increased when it is combined with Cilazapril.	Approved
Cilnidipine	Silodosin may increase the hypotensive activities of Cilnidipine.	Approved
Cimetidine	The serum concentration of Silodosin can be increased when it is combined with Cimetidine.	Approved
Cinnarizine	Silodosin may increase the hypotensive activities of Cinnarizine.	Approved
Ciprofloxacin	The serum concentration of Silodosin can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Cirazoline	Silodosin may decrease the vasoconstricting activities of Cirazoline.	Experimental
Citalopram	The serum concentration of Silodosin can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Silodosin can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Silodosin can be decreased when combined with Clemastine.	Approved
Clenbuterol	Silodosin may decrease the vasoconstricting activities of Clenbuterol.	Approved, Vet Approved
Clevidipine	Silodosin may increase the hypotensive activities of Clevidipine.	Approved
Clofazimine	The serum concentration of Silodosin can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomipramine	The serum concentration of Silodosin can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonidine	Silodosin may decrease the vasoconstricting activities of Clonidine.	Approved
Clotrimazole	The serum concentration of Silodosin can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Cobicistat	The serum concentration of Silodosin can be increased when it is combined with Cobicistat.	Approved
Colchicine	The serum concentration of Silodosin can be increased when it is combined with Colchicine.	Approved
Colforsin	The serum concentration of Silodosin can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Silodosin can be increased when it is combined with Conivaptan.	Approved, Investigational
Crizotinib	The serum concentration of Silodosin can be increased when it is combined with Crizotinib.	Approved
Cyclophosphamide	The serum concentration of Silodosin can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Silodosin can be increased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Dabrafenib	The serum concentration of Silodosin can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Silodosin can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Silodosin can be increased when it is combined with Dactinomycin.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Silodosin.	Investigational
Darodipine	Silodosin may increase the hypotensive activities of Darodipine.	Experimental
Darunavir	The serum concentration of Silodosin can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Silodosin can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Silodosin can be increased when it is combined with Daunorubicin.	Approved
Deferasirox	The serum concentration of Silodosin can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Silodosin can be decreased when combined with Delavirdine.	Approved
Desipramine	The serum concentration of Silodosin can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Silodosin can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Silodosin can be increased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexmedetomidine	Silodosin may decrease the vasoconstricting activities of Dexmedetomidine.	Approved, Vet Approved
Dextromethorphan	The serum concentration of Silodosin can be increased when it is combined with Dextromethorphan.	Approved
Diclofenac	The serum concentration of Silodosin can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Digoxin	The serum concentration of Silodosin can be increased when it is combined with Digoxin.	Approved
Dihydroergotamine	The serum concentration of Silodosin can be increased when it is combined with Dihydroergotamine.	Approved
Diltiazem	The serum concentration of Silodosin can be increased when it is combined with Diltiazem.	Approved
Dipivefrin	Silodosin may decrease the vasoconstricting activities of Dipivefrin.	Approved
Dipyridamole	The serum concentration of Silodosin can be increased when it is combined with Dipyridamole.	Approved
Dobutamine	Silodosin may decrease the vasoconstricting activities of Dobutamine.	Approved
Doxazosin	The serum concentration of Silodosin can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Silodosin can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Silodosin can be increased when it is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Silodosin can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Silodosin can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The serum concentration of Silodosin can be increased when it is combined with Dronedarone.	Approved
Droxidopa	Silodosin may decrease the vasoconstricting activities of Droxidopa.	Approved, Investigational
Efavirenz	The serum concentration of Silodosin can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efonidipine	Silodosin may increase the hypotensive activities of Efonidipine.	Approved
Elbasvir	The serum concentration of Silodosin can be increased when it is combined with Elbasvir.	Approved
Enalapril	The serum concentration of Silodosin can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Silodosin can be increased when it is combined with Enzalutamide.	Approved
Eperisone	Silodosin may increase the hypotensive activities of Eperisone.	Approved, Investigational
Ephedrine	Silodosin may decrease the vasoconstricting activities of Ephedrine.	Approved
Epinephrine	Silodosin may decrease the vasoconstricting activities of Epinephrine.	Approved, Vet Approved
Ergonovine	The serum concentration of Silodosin can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Silodosin can be increased when it is combined with Ergotamine.	Approved
Erythromycin	The serum concentration of Silodosin can be increased when it is combined with Erythromycin.	Approved, Vet Approved
Eslicarbazepine acetate	The serum concentration of Silodosin can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmolol	Esmolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Estramustine	The serum concentration of Silodosin can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Silodosin can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Silodosin can be decreased when it is combined with Estrone.	Approved
Etilefrine	Silodosin may decrease the vasoconstricting activities of Etilefrine.	Withdrawn
Etoposide	The serum concentration of Silodosin can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Silodosin can be increased when it is combined with Etravirine.	Approved
Felodipine	The serum concentration of Silodosin can be increased when it is combined with Felodipine.	Approved, Investigational
Fendiline	Silodosin may increase the hypotensive activities of Fendiline.	Withdrawn
Fenoterol	Silodosin may decrease the vasoconstricting activities of Fenoterol.	Approved
Fentanyl	The serum concentration of Silodosin can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The serum concentration of Silodosin can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Silodosin can be increased when it is combined with Fidaxomicin.	Approved
Fluconazole	The serum concentration of Silodosin can be increased when it is combined with Fluconazole.	Approved
Flunarizine	Silodosin may increase the hypotensive activities of Flunarizine.	Approved
Fluoxetine	The serum concentration of Silodosin can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Silodosin can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Silodosin can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Silodosin can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluvoxamine	The serum concentration of Silodosin can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formoterol	Silodosin may decrease the vasoconstricting activities of Formoterol.	Approved, Investigational
Fosamprenavir	The metabolism of Silodosin can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Silodosin can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The metabolism of Silodosin can be increased when combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Silodosin can be increased when it is combined with Fusidic Acid.	Approved
Gabapentin	Silodosin may increase the hypotensive activities of Gabapentin.	Approved, Investigational
Gallopamil	Silodosin may increase the hypotensive activities of Gallopamil.	Investigational
Gefitinib	The serum concentration of Silodosin can be increased when it is combined with Gefitinib.	Approved, Investigational
Genistein	The serum concentration of Silodosin can be increased when it is combined with Genistein.	Investigational
Glyburide	The serum concentration of Silodosin can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Silodosin can be increased when it is combined with Gramicidin D.	Approved
Grepafloxacin	The serum concentration of Silodosin can be increased when it is combined with Grepafloxacin.	Withdrawn
Guanabenz	Silodosin may decrease the vasoconstricting activities of Guanabenz.	Approved
Guanfacine	Silodosin may decrease the vasoconstricting activities of Guanfacine.	Approved, Investigational
Haloperidol	The serum concentration of Silodosin can be increased when it is combined with Haloperidol.	Approved
Hexoprenaline	Silodosin may decrease the vasoconstricting activities of Hexoprenaline.	Approved, Withdrawn
Higenamine	Silodosin may decrease the vasoconstricting activities of Higenamine.	Investigational
Hydrocortisone	The serum concentration of Silodosin can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Idelalisib	The serum concentration of Silodosin can be increased when it is combined with Idelalisib.	Approved
Imatinib	The serum concentration of Silodosin can be increased when it is combined with Imatinib.	Approved
Imipramine	The serum concentration of Silodosin can be increased when it is combined with Imipramine.	Approved
Indenolol	Indenolol may increase the orthostatic hypotensive activities of Silodosin.	Withdrawn
Indinavir	The serum concentration of Silodosin can be increased when it is combined with Indinavir.	Approved
Indomethacin	The serum concentration of Silodosin can be increased when it is combined with Indomethacin.	Approved, Investigational
Indoramin	Silodosin may increase the antihypertensive activities of Indoramin.	Withdrawn
Isavuconazonium	The serum concentration of Silodosin can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isoetarine	Silodosin may decrease the vasoconstricting activities of Isoetarine.	Approved
Isoprenaline	Silodosin may decrease the vasoconstricting activities of Isoprenaline.	Approved
Isoxsuprine	Silodosin may decrease the vasoconstricting activities of Isoxsuprine.	Approved, Withdrawn
Isradipine	The metabolism of Silodosin can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Silodosin can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Silodosin can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Silodosin can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Silodosin can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketoconazole	The serum concentration of Silodosin can be increased when it is combined with Ketoconazole.	Approved, Investigational
Labetalol	Labetalol may increase the antihypertensive activities of Silodosin.	Approved
Lacidipine	Silodosin may increase the hypotensive activities of Lacidipine.	Approved
Lamotrigine	Silodosin may increase the hypotensive activities of Lamotrigine.	Approved, Investigational
Landiolol	Aop200704 may increase the orthostatic hypotensive activities of Silodosin.	Investigational
Lansoprazole	The serum concentration of Silodosin can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lapatinib	The serum concentration of Silodosin can be increased when it is combined with Lapatinib.	Approved, Investigational
Lercanidipine	Silodosin may increase the hypotensive activities of Lercanidipine.	Approved, Investigational
Levofloxacin	The serum concentration of Silodosin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levothyroxine	The serum concentration of Silodosin can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Silodosin can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Liothyronine	The serum concentration of Silodosin can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Silodosin can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Silodosin can be increased when it is combined with Lisinopril.	Approved, Investigational
Lofexidine	Silodosin may decrease the vasoconstricting activities of Lofexidine.	Approved, Investigational
Lomitapide	The serum concentration of Silodosin can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Silodosin can be increased when it is combined with Loperamide.	Approved
Lopinavir	The serum concentration of Silodosin can be increased when it is combined with Lopinavir.	Approved
Loratadine	The serum concentration of Silodosin can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Silodosin can be increased when it is combined with Losartan.	Approved
Lovastatin	The serum concentration of Silodosin can be increased when it is combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Silodosin can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Silodosin can be decreased when it is combined with Lumacaftor.	Approved
Magnesium Sulfate	Silodosin may increase the hypotensive activities of Magnesium Sulfate.	Approved, Vet Approved
Manidipine	Silodosin may increase the hypotensive activities of Manidipine.	Approved
Maprotiline	The serum concentration of Silodosin can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Silodosin can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mefloquine	The serum concentration of Silodosin can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Silodosin can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Mephentermine	Silodosin may decrease the vasoconstricting activities of Mephentermine.	Approved
Meprobamate	The serum concentration of Silodosin can be increased when it is combined with Meprobamate.	Approved, Illicit
Metaraminol	Silodosin may decrease the vasoconstricting activities of Metaraminol.	Approved, Investigational
Methadone	The serum concentration of Silodosin can be increased when it is combined with Methadone.	Approved
Methoxamine	Silodosin may decrease the vasoconstricting activities of Methoxamine.	Approved
Methyldopa	Silodosin may decrease the vasoconstricting activities of Methyldopa.	Approved
Metoprolol	The serum concentration of Silodosin can be increased when it is combined with Metoprolol.	Approved, Investigational
Mibefradil	The serum concentration of Silodosin can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Silodosin can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Silodosin can be increased when it is combined with Midazolam.	Approved, Illicit
Midodrine	Silodosin may decrease the vasoconstricting activities of Midodrine.	Approved
Mifepristone	The serum concentration of Silodosin can be increased when it is combined with Mifepristone.	Approved, Investigational
Mirabegron	Silodosin may decrease the vasoconstricting activities of Mirabegron.	Approved
Mitomycin	The serum concentration of Silodosin can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Silodosin can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Silodosin can be increased when it is combined with Mitoxantrone.	Approved, Investigational
Modafinil	The serum concentration of Silodosin can be decreased when it is combined with Modafinil.	Approved, Investigational
Morphine	The serum concentration of Silodosin can be increased when it is combined with Morphine.	Approved, Investigational
Nadolol	Nadolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Nafcillin	The serum concentration of Silodosin can be decreased when it is combined with Nafcillin.	Approved
Naftopidil	Silodosin may increase the hypotensive activities of Naftopidil.	Investigational
Naltrexone	The serum concentration of Silodosin can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naphazoline	Silodosin may decrease the vasoconstricting activities of Naphazoline.	Approved
Naringenin	The serum concentration of Silodosin can be increased when it is combined with Naringenin.	Experimental
Nebivolol	Silodosin may decrease the vasoconstricting activities of Nebivolol.	Approved, Investigational
Nefazodone	The serum concentration of Silodosin can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Silodosin can be increased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Silodosin can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Silodosin can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Silodosin can be increased when combined with Nevirapine.	Approved
Nicardipine	The serum concentration of Silodosin can be increased when it is combined with Nicardipine.	Approved
Nifedipine	The serum concentration of Silodosin can be increased when it is combined with Nifedipine.	Approved
Niguldipine	Silodosin may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The serum concentration of Silodosin can be increased when it is combined with Nilotinib.	Approved, Investigational
Niludipine	Silodosin may increase the hypotensive activities of Niludipine.	Experimental
Nilvadipine	Silodosin may increase the hypotensive activities of Nilvadipine.	Approved
Nimesulide	Silodosin may increase the hypotensive activities of Nimesulide.	Approved, Withdrawn
Nimodipine	Silodosin may increase the hypotensive activities of Nimodipine.	Approved
Nisoldipine	The serum concentration of Silodosin can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Silodosin can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Silodosin can be increased when it is combined with Nitrendipine.	Approved
Norepinephrine	Silodosin may decrease the vasoconstricting activities of Norepinephrine.	Approved
Norethisterone	The serum concentration of Silodosin can be decreased when it is combined with Norethisterone.	Approved
Olaparib	The metabolism of Silodosin can be decreased when combined with Olaparib.	Approved
Olodaterol	Silodosin may decrease the vasoconstricting activities of Olodaterol.	Approved
Omeprazole	The serum concentration of Silodosin can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Orciprenaline	Silodosin may decrease the vasoconstricting activities of Orciprenaline.	Approved
Osimertinib	The serum concentration of Silodosin can be increased when it is combined with Osimertinib.	Approved
Oxprenolol	Oxprenolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Oxymetazoline	Silodosin may decrease the vasoconstricting activities of Oxymetazoline.	Approved
P-Nitrophenol	The serum concentration of Silodosin can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Silodosin can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Silodosin can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Silodosin can be increased when it is combined with Palmitic Acid.	Experimental
Pantoprazole	The serum concentration of Silodosin can be increased when it is combined with Pantoprazole.	Approved
Paroxetine	The serum concentration of Silodosin can be increased when it is combined with Paroxetine.	Approved, Investigational
Penbutolol	Penbutolol may increase the orthostatic hypotensive activities of Silodosin.	Approved, Investigational
Pentobarbital	The metabolism of Silodosin can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perhexiline	Silodosin may increase the hypotensive activities of Perhexiline.	Approved
Perindopril	The serum concentration of Silodosin can be increased when it is combined with Perindopril.	Approved
Phenobarbital	The metabolism of Silodosin can be increased when combined with Phenobarbital.	Approved
Phenylephrine	Silodosin may decrease the vasoconstricting activities of Phenylephrine.	Approved
Phenylpropanolamine	Silodosin may decrease the vasoconstricting activities of Phenylpropanolamine.	Approved, Vet Approved, Withdrawn
Phenytoin	The metabolism of Silodosin can be increased when combined with Phenytoin.	Approved, Vet Approved
Pimozide	The serum concentration of Silodosin can be increased when it is combined with Pimozide.	Approved
Pinaverium	Silodosin may increase the hypotensive activities of Pinaverium.	Approved
Pindolol	Pindolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Pirbuterol	Silodosin may decrease the vasoconstricting activities of Pirbuterol.	Approved
Platelet Activating Factor	The serum concentration of Silodosin can be decreased when it is combined with Platelet Activating Factor.	Experimental
Ponatinib	The serum concentration of Silodosin can be increased when it is combined with Ponatinib.	Approved
Posaconazole	The serum concentration of Silodosin can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Practolol	Practolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Pravastatin	The serum concentration of Silodosin can be increased when it is combined with Pravastatin.	Approved
Prazosin	The serum concentration of Silodosin can be increased when it is combined with Prazosin.	Approved
Prednisone	The serum concentration of Silodosin can be increased when it is combined with Prednisone.	Approved, Vet Approved
Pregabalin	Silodosin may increase the hypotensive activities of Pregabalin.	Approved, Illicit, Investigational
Prenylamine	Silodosin may increase the hypotensive activities of Prenylamine.	Withdrawn
Primidone	The metabolism of Silodosin can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Silodosin can be increased when it is combined with Probenecid.	Approved
Procaterol	Silodosin may decrease the vasoconstricting activities of Procaterol.	Approved
Progesterone	The serum concentration of Silodosin can be increased when it is combined with Progesterone.	Approved, Vet Approved
Promethazine	The serum concentration of Silodosin can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Silodosin can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Silodosin can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Silodosin can be increased when it is combined with Protriptyline.	Approved
Pseudoephedrine	Silodosin may decrease the vasoconstricting activities of Pseudoephedrine.	Approved
Quercetin	The serum concentration of Silodosin can be increased when it is combined with Quercetin.	Experimental
Quinacrine	The serum concentration of Silodosin can be increased when it is combined with Quinacrine.	Approved
Quinidine	The serum concentration of Silodosin can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Silodosin can be increased when it is combined with Quinine.	Approved
Ranitidine	The serum concentration of Silodosin can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Silodosin can be increased when it is combined with Ranolazine.	Approved, Investigational
Reboxetine	The serum concentration of Silodosin can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Silodosin can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Silodosin can be increased when it is combined with Reserpine.	Approved
Rifabutin	The metabolism of Silodosin can be increased when combined with Rifabutin.	Approved
Rifampicin	The serum concentration of Silodosin can be increased when it is combined with Rifampicin.	Approved
Rifapentine	The metabolism of Silodosin can be increased when combined with Rifapentine.	Approved
Rilmenidine	Silodosin may decrease the vasoconstricting activities of Rilmenidine.	Investigational
Rilpivirine	The serum concentration of Silodosin can be increased when it is combined with Rilpivirine.	Approved
Risedronate	Silodosin may increase the hypotensive activities of Risedronate.	Approved, Investigational
Ritobegron	Silodosin may decrease the vasoconstricting activities of Ritobegron.	Investigational
Ritodrine	Silodosin may decrease the vasoconstricting activities of Ritodrine.	Approved
Ritonavir	The serum concentration of Silodosin can be increased when it is combined with Ritonavir.	Approved, Investigational
Rolapitant	The serum concentration of Silodosin can be increased when it is combined with Rolapitant.	Approved
Salbutamol	Silodosin may decrease the vasoconstricting activities of Salbutamol.	Approved, Vet Approved
Salmeterol	Silodosin may decrease the vasoconstricting activities of Salmeterol.	Approved
Saquinavir	The serum concentration of Silodosin can be increased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Silodosin can be increased when it is combined with Scopolamine.	Approved
Selegiline	The serum concentration of Silodosin can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Sertraline	The serum concentration of Silodosin can be increased when it is combined with Sertraline.	Approved
Sildenafil	Sildenafil may increase the hypotensive activities of Silodosin.	Approved, Investigational
Siltuximab	The serum concentration of Silodosin can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Silodosin can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Silodosin can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Silodosin can be increased when it is combined with Sirolimus.	Approved, Investigational
Solabegron	Silodosin may decrease the vasoconstricting activities of Solabegron.	Investigational
Sorafenib	The serum concentration of Silodosin can be increased when it is combined with Sorafenib.	Approved, Investigational
Sotalol	Sotalol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Spironolactone	The serum concentration of Silodosin can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The serum concentration of Silodosin can be decreased when it is combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Silodosin can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Silodosin can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Silodosin can be decreased when it is combined with Streptozocin.	Approved
Sulfinpyrazone	The serum concentration of Silodosin can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Silodosin can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Silodosin can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Silodosin can be increased when it is combined with Sunitinib.	Approved, Investigational
Synephrine	Silodosin may decrease the vasoconstricting activities of Synephrine.	Experimental
Tacrine	The serum concentration of Silodosin can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Silodosin can be increased when it is combined with Tacrolimus.	Approved, Investigational
Tadalafil	Tadalafil may increase the hypotensive activities of Silodosin.	Approved, Investigational
Tamoxifen	The serum concentration of Silodosin can be increased when it is combined with Tamoxifen.	Approved
Tamsulosin	Tamsulosin may increase the antihypertensive activities of Silodosin.	Approved, Investigational
Taurocholic Acid	The serum concentration of Silodosin can be increased when it is combined with Taurocholic Acid.	Experimental
Telaprevir	The serum concentration of Silodosin can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of Silodosin can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Silodosin can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Silodosin can be increased when it is combined with Temsirolimus.	Approved
Terazosin	The serum concentration of Silodosin can be increased when it is combined with Terazosin.	Approved
Terbutaline	Silodosin may decrease the vasoconstricting activities of Terbutaline.	Approved
Terfenadine	The serum concentration of Silodosin can be increased when it is combined with Terfenadine.	Withdrawn
Tesmilifene	The serum concentration of Silodosin can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Silodosin can be increased when it is combined with Testosterone.	Approved, Investigational
Ticagrelor	The serum concentration of Silodosin can be increased when it is combined with Ticagrelor.	Approved
Ticlopidine	The metabolism of Silodosin can be decreased when combined with Ticlopidine.	Approved
Timolol	Timolol may increase the orthostatic hypotensive activities of Silodosin.	Approved
Tizanidine	Silodosin may decrease the vasoconstricting activities of Tizanidine.	Approved
Tocilizumab	The serum concentration of Silodosin can be decreased when it is combined with Tocilizumab.	Approved
Tolfenamic Acid	Silodosin may increase the hypotensive activities of Tolfenamic Acid.	Approved
Tolvaptan	The serum concentration of Silodosin can be increased when it is combined with Tolvaptan.	Approved
Tranilast	Silodosin may increase the hypotensive activities of Tranilast.	Approved, Investigational
Trazodone	The serum concentration of Silodosin can be decreased when it is combined with Trazodone.	Approved, Investigational
Trifluoperazine	The serum concentration of Silodosin can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Silodosin can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimazosin	Silodosin may increase the antihypertensive activities of Trimazosin.	Experimental
Trimethoprim	The serum concentration of Silodosin can be increased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Silodosin can be increased when it is combined with Trimipramine.	Approved
Tulobuterol	Silodosin may decrease the vasoconstricting activities of Tulobuterol.	Investigational
Udenafil	Udenafil may increase the hypotensive activities of Silodosin.	Approved, Investigational
Vardenafil	Vardenafil may increase the hypotensive activities of Silodosin.	Approved
Venlafaxine	The serum concentration of Silodosin can be increased when it is combined with Venlafaxine.	Approved
Verapamil	The serum concentration of Silodosin can be increased when it is combined with Verapamil.	Approved
Vinblastine	The serum concentration of Silodosin can be increased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Silodosin can be increased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Silodosin can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vinpocetine	Silodosin may increase the hypotensive activities of Vinpocetine.	Investigational
Voriconazole	The serum concentration of Silodosin can be increased when it is combined with Voriconazole.	Approved, Investigational
Xylometazoline	Silodosin may increase the hypotensive activities of Xylometazoline.	Approved
Ziconotide	Silodosin may increase the hypotensive activities of Ziconotide.	Approved
Zimelidine	The serum concentration of Silodosin can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Silodosin can be decreased when combined with Ziprasidone.	Approved

Food Interactions

The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49%

References

Synthesis Reference

Not Available

General References

Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. [PubMed:18042003 ]
Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. [PubMed:17603160 ]

External Links

Resource	Link
KEGG Drug	D01965
PubChem Compound	5312125
PubChem Substance	175427058
ChemSpider	4471557
BindingDB	50160154
ChEBI	135929
ChEMBL	CHEMBL24778
PharmGKB	PA165291889
Drug Product Database	20659
RxList	http://www.rxlist.com/rapaflo-capsules-drug.htm
Drugs.com	http://www.drugs.com/cdi/silodosin.html
Wikipedia	Silodosin

ATC Codes

G04CA04 — Silodosin

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Download (846 KB)

MSDS

Download (479 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
2	Completed	Treatment	Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome	1
2	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	1
2	Completed	Treatment	Nocturia / Prostatic Hyperplasia	1
2	Completed	Treatment	Renal Stones / Ureteral Calculus / Urolithiasis	1
2	Completed	Treatment	Urinary Tract Stones	1
2	Recruiting	Treatment	Premature Ejaculation	1
3	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	4
3	Recruiting	Supportive Care	Malignant Neoplasm of Prostate / Urinary Problems	1
3	Terminated	Treatment	Expulsive Medical Therapy / Renal Stones	1
3	Withdrawn	Treatment	Renal Stones	1
4	Completed	Treatment	Benign Prostatic Hyperplasia (BPH)	2
4	Completed	Treatment	Benign Prostatic Hyperplasia (BPH) / Nocturia	1
4	Completed	Treatment	Benign Prostatic Hypertrophy (BPH)	1
4	Completed	Treatment	Neurogenic Bladder Dysfunction / Voiding Dysfunction	1
4	Completed	Treatment	Ureteral Stones	1
4	Terminated	Treatment	Ureteral Calculus / Ureteral Stones / Ureterolithiasis	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral	4 mg/1
Capsule	Oral	8 mg/1
Capsule	Oral	4 mg
Capsule	Oral	8 mg

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5387603	No	1998-12-01	2018-12-01	US
US5403847	No	1992-11-13	2012-11-13	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	105 - 109°C	FDA label
water solubility	Very slightly soluble	FDA label

Predicted Properties

Property	Value	Source
Water Solubility	0.0111 mg/mL	ALOGPS
logP	2.96	ALOGPS
logP	3.05	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Acidic)	14.87	ChemAxon
pKa (Strongest Basic)	9.66	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	97.05 Å²	ChemAxon
Rotatable Bond Count	14	ChemAxon
Refractivity	128.92 m³·mol^-1	ChemAxon
Polarizability	49.89 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.7383
Caco-2 permeable	-	0.5847
P-glycoprotein substrate	Substrate	0.8467
P-glycoprotein inhibitor I	Non-inhibitor	0.5833
P-glycoprotein inhibitor II	Inhibitor	0.7864
Renal organic cation transporter	Non-inhibitor	0.7288
CYP450 2C9 substrate	Non-substrate	0.8226
CYP450 2D6 substrate	Non-substrate	0.6362
CYP450 3A4 substrate	Substrate	0.6585
CYP450 1A2 substrate	Non-inhibitor	0.7439
CYP450 2C9 inhibitor	Non-inhibitor	0.7569
CYP450 2D6 inhibitor	Non-inhibitor	0.5958
CYP450 2C19 inhibitor	Non-inhibitor	0.5562
CYP450 3A4 inhibitor	Inhibitor	0.7424
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.5723
Ames test	Non AMES toxic	0.6667
Carcinogenicity	Non-carcinogens	0.8529
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4845 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.98
hERG inhibition (predictor II)	Inhibitor	0.8366

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as indolecarboxamides and derivatives. These are compounds containing a carboxamide group attached to an indole.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Indoles and derivatives

Direct Parent

Indolecarboxamides and derivatives

Alternative Parents

Dialkylarylamines / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Aralkylamines / Vinylogous amides / 1,3-aminoalcohols / Amino acids and derivatives / Primary carboxylic acid amides / Dialkylamines

Substituents

Indolecarboxamide derivative / Phenoxy compound / Phenol ether / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Alkyl aryl ether / Aralkylamine / Monocyclic benzene moiety / Benzenoid / Vinylogous amide

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

Not Available

Targets

Details

1. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1A
Uniprot ID:: P35348
Molecular Weight:: 51486.005 Da

References

Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]

Details

2. Alpha-1B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Protein heterodimerization activity
Specific Function:: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:: ADRA1B
Uniprot ID:: P35368
Molecular Weight:: 56835.375 Da

References

Lepor H, Hill LA: Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy. 2010 Dec;30(12):1303-12. doi: 10.1592/phco.30.12.1303. [PubMed:21114397 ]

Details

3. Alpha-1D adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: antagonist

General Function:: Alpha1-adrenergic receptor activity
Specific Function:: This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:: ADRA1D
Uniprot ID:: P25100
Molecular Weight:: 60462.205 Da

References

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]

Enzymes

Details

1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]
Cantrell MA, Bream-Rouwenhorst HR, Hemerson P, Magera JS Jr: Silodosin for benign prostatic hyperplasia. Ann Pharmacother. 2010 Feb;44(2):302-10. doi: 10.1345/aph.1M320. Epub 2010 Jan 13. [PubMed:20071497 ]

Details

2. UDP-glucuronosyltransferase 2B7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Glucuronosyltransferase activity
Specific Function:: UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:: UGT2B7
Uniprot ID:: P16662
Molecular Weight:: 60694.12 Da

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]

Details

2. Phosphatidylcholine translocator ABCB4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent phospholipid efflux translocator that acts as a positive regulator of biliary lipid secretion. Functions as a floppase that translocates specifically phosphatidylcholine (PC) from the inner to the outer leaflet of the canalicular membrane bilayer into the canaliculi of hepatocytes. Translocation of PC makes the biliary phospholipids available for extraction into the canaliculi ...
Gene Name:: ABCB4
Uniprot ID:: P21439
Molecular Weight:: 141521.845 Da

References

Matsubara Y, Kanazawa T, Kojima Y, Abe Y, Kobayashi K, Kanbe H, Harada H, Momose Y, Terakado S, Adachi Y, Midgley I: [Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. [PubMed:16518089 ]

Drug created on March 19, 2008 10:17 / Updated on July 11, 2017 02:02

Get DrugBank to go!

Structure for DB06207 (Silodosin)

Targets

References

References

References

Enzymes

References

Transporters

References

References